Company intelligence / Profile preview

Advanced Nuclear Medicine Ingredients

Herstal, Wallonie, Belgium

Ownership: Public · TLX
Development stage: Other

Overview

ANMI, now part of Telix Pharmaceuticals, developed and commercialized the illumet (gallium-68 PSMA) kit for PET imaging of prostate cancer. The product enables rapid, “cold kit” preparation of gallium-68-PSMA tracer for diagnostic use. The product is on the market in the US and in late-stage clinical development in Europe. Tc-99m-iPSMA for SPECT/CT is also being developed/licensed for broader accessibility[8][10].

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall molecule
Industry: Medical Imaging

Partnerships

Instituto Nacional de Investigaciones Nucleares (ININ, Mexico) (for Tc-99m iPSMA license)[8]

Beyond the preview

Go deeper on Advanced Nuclear Medicine Ingredients.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Nuclear Medicine Ingredients.

Explore the full profile